Search

Your search keyword '"Joseph Odin"' showing total 45 results

Search Constraints

Start Over You searched for: "Joseph Odin" Remove constraint "Joseph Odin"
45 results on '"Joseph Odin"'

Search Results

1. Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug‐Induced Liver Injury

2. Correction: Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.

3. Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.

4. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]

5. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

7. Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIES

8. Primary Biliary Cirrhosis: Environmental Risk Factors

9. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study

10. Atorvastatin Does Not Improve Liver Biochemistries or Mayo Risk Score in Primary Biliary Cirrhosis.

11. Correction: Cytokine profiles in acute liver injury—Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.

13. Cytokine profiles in acute liver injury—Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.

14. Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response.

15. High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens.

16. Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series.

17. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.

18. The features of mucosa-associated microbiota in primary sclerosing cholangitis.

20. ABSTRACTS.

21. Primary biliary cirrhosis: Environmental risk factors.

22. Vaccination as a Triggering Event for Autoimmune Hepatitis.

23. Genes and (auto)immunity in primary biliary cirrhosis.

25. CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

26. CymaBay Therapeutics Announces Presentations at Digestive Disease Week(R) 2022

27. CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress 2021

28. CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress 2021

29. CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress(TM) 2021

30. CymaBay Therapeutics Announces Presentations During The International Liver Congress 2021

31. CymaBay Therapeutics Announces Presentations During The International Liver Congress 2021

32. CymaBay Therapeutics Announces Presentations During The International Liver Congress(TM) 2021

33. CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress 2020

34. CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress 2020

36. CymaBay Therapeutics Announces Presentations at The Liver Meeting(r) 2019

37. CymaBay Therapeutics Announces Presentations at The Liver Meeting(R) 2019

38. CymaBay Therapeutics Announces Multiple Presentations at DDW 2019

39. CymaBay Therapeutics Announces Multiple Presentations at DDW 2019

40. CymaBay Therapeutics Announces Multiple Presentations at DDW 2019

43. Icahn School of Medicine at Mount Sinai Joins Drug-Induced Liver Injury Network

44. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.

45. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.

Catalog

Books, media, physical & digital resources